Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 6-Week, Multicenter, Double-Blind, Double-Dummy, Randomized Comparison of the Efficacy and Safety of Sustained-Release Formulation Quetiapine Fumarate (SEROQUEL) and Placebo in the Treatment of Acutely Ill Patients With Schizophrenia

NCT00085891 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT00085891
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00085891 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 6-Week, Multicenter, Double-Blind, Double-Dummy, Randomized Comparison of the Efficacy and Safety of Sustained-Release Formulation Quetiapine Fumarate (SEROQUEL) and Placebo in the Treatment of Acutely Ill Patients With Schizophrenia
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Completed
Start date
June 30, 2004
Completion date
September 30, 2005
Enrollment
535
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia